Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $25,424 | $25,979 | $26,323 | $28,190 | $33,424 |
| Gross Profit | $4,737 | $19,525 | $19,917 | $19,739 | $20,566 |
| Operating Income | $9,139 | $7,639 | $9,566 | $7,897 | $7,258 |
| Net Income | $7,264 | $5,893 | $6,552 | $6,717 | $4,090 |
Over the five-year period, Amgen’s revenue exhibited a generally upward trend, growing from USD 25,424 million in 2020 to USD 33,424 million in 2024. Although the annual increases varied—with modest gains of around 2%–3% in 2021 and 2022, a stronger rise of roughly 7% in 2023, and a notable jump near 18% in 2024—the overall trend is positive, indicating an expanding top line. In contrast, the gross profit figures show some volatility. The reported amount in 2020 was USD 4,737 million, which markedly rose to USD 19,525 million in 2021, representing an extraordinary swing that could reflect a change in accounting practices, product mix, or cost recognition methodology. Subsequently, gross profit stabilized around the USD 19,700–20,500 million range, suggesting that the earlier spike might be a one-off or reclassification effect rather than sustained operational improvement. On the profitability front, operating income and net income reveal mixed performance. Operating income peaked at USD 9,139 million in 2020 but then declined to USD 7,639 million in 2021, rebounding to USD 9,566 million in 2022 before falling again to USD 7,897 million in 2023 and further to USD 7,258 million in 2024. Net income followed a similar pattern, starting at USD 7,264 million in 2020, dipping by nearly 19% to USD 5,893 million in 2021, modestly recovering to USD 6,552 million in 2022 and USD 6,717 million in 2023, but then experiencing a sharp decline of about 39% to USD 4,090 million in 2024. This significant drop in 2024 net income may indicate rising costs, operational challenges, or margin pressures in a competitive biotechnology landscape. Overall, while revenue growth underscores market expansion and potential, the volatility in margins and earnings raises concerns about cost management and operational sustainability in the near term.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.